These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 9021203)

  • 61. Sensitivity pattern of gram negative bacilli to three beta-lactam/beta-lactamase inhibitor combinations using the automated API system.
    Anuradha K; Sailaja VV; Umabala P; Satheesh T; Lakshmi V
    Indian J Med Microbiol; 2007 Jul; 25(3):203-8. PubMed ID: 17901635
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.
    Kuti JL; Nightingale CH; Quintiliani R; Nicolau D
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):51-7. PubMed ID: 12376031
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ampicillin and ampicillin-sulbactam dilution tests with mixed cultures of Bacteroides fragilis, Escherichia coli and Enterococcus.
    Heilmann F
    Infection; 1993; 21(3):187-90. PubMed ID: 8365818
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.
    Pfaller M; Barry A; Fuchs P; Gerlach E; Hardy D; McLaughlin J
    Eur J Clin Microbiol Infect Dis; 1993 Mar; 12(3):200-5. PubMed ID: 8389705
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Pagani L; Migliavacca R; Luzzaro F; Giacobone E; Perilli M; Micheletti P; Amicosante G
    Chemotherapy; 1998; 44(6):377-84. PubMed ID: 9755296
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group.
    Tan JS; Wishnow RM; Talan DA; Duncanson FP; Norden CW
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1580-6. PubMed ID: 8215266
    [TBL] [Abstract][Full Text] [Related]  

  • 67. In vitro activity of ceftriaxone combined with tazobactam against anaerobic bacteria.
    Wüst J; Hardegger U
    Eur J Clin Microbiol Infect Dis; 1994 Feb; 13(2):177-81. PubMed ID: 8013494
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 69. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
    Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
    J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro].
    Blahová J; Hupková M; Krcméry V
    Cas Lek Cesk; 1995 Sep; 134(17):558-61. PubMed ID: 7553760
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002.
    Frei CR; Burgess DS
    Clin Ther; 2008 Dec; 30(12):2335-41. PubMed ID: 19167592
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
    Livermore DM; Seetulsingh P
    J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antimicrobial susceptibility of common pathogens isolated from postoperative intra-abdominal infections in Japan.
    Takesue Y; Kusachi S; Mikamo H; Sato J; Watanabe A; Kiyota H; Iwata S; Kaku M; Hanaki H; Sumiyama Y; Kitagawa Y; Nakajima K; Ueda T; Uchino M; Mizuguchi T; Ambo Y; Konosu M; Ishibashi K; Matsuda A; Hase K; Harihara Y; Okabayashi K; Seki S; Hara T; Matsui K; Matsuo Y; Kobayashi M; Kubo S; Uchiyama K; Shimizu J; Kawabata R; Ohge H; Akagi S; Oka M; Wakatsuki T; Suzuki K; Okamoto K; Yanagihara K
    J Infect Chemother; 2018 May; 24(5):330-340. PubMed ID: 29555391
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles.
    Chen HY; Bonfiglio G; Allen M; Piper D; Edwardson T; McVey D; Livermore DM
    J Antimicrob Chemother; 1993 Aug; 32(2):247-66. PubMed ID: 8226427
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients.
    Casellas JM; Tomé G; Bantar C; Bertolini P; Blázquez N; Borda N; Couto E; Cudmani N; Guerrera J; Juárez MJ; López T; Littvik A; Méndez E; Notario R; Ponce G; Quinteros M; Salamone F; Sparo M; Sutich E; Vaylet S; Wolff L
    Diagn Microbiol Infect Dis; 2003 Nov; 47(3):527-37. PubMed ID: 14596972
    [TBL] [Abstract][Full Text] [Related]  

  • 76. In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates.
    Cormican M; Corbett-Feeney G; Kelly S; Hughes D; Flynn J; Jones RN
    Ir J Med Sci; 1998; 167(3):155-9. PubMed ID: 9780564
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
    Hou F; Li J; Gao L; Chen Y
    Chin Med J (Engl); 1998 Nov; 111(11):1039-43. PubMed ID: 11189212
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.
    Aronoff SC; Jacobs MR; Johenning S; Yamabe S
    Antimicrob Agents Chemother; 1984 Oct; 26(4):580-2. PubMed ID: 6097169
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria.
    Chang SC; Hsu LY; Luh KT; Hsieh WC
    J Formos Med Assoc; 1991 Oct; 90(10):947-52. PubMed ID: 1685175
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group.
    Falagas ME; McDermott L; Snydman DR
    Antimicrob Agents Chemother; 1997 Sep; 41(9):2047-9. PubMed ID: 9303414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.